Issue

Vol. 36 No. 1 (2024): Vol 36 Issue 1, 2024

Copyright (c) 2023 K.K.Rajasekhar Komarla

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Benzofuran-Isoxazole Hybrids: Synthesis, Antimicrobial Activity and Dual Target Docking Studies

https://doi.org/10.14233/ajchem.2024.30779
Bhargavi Posinasetty
1 Department of Public Health, University of Southern Mississippi, MS-39406, USA 2 Government Dental College and Research Institute, Bellary-583104, India
https://orcid.org/0009-0004-3220-5219
Rajendra Prasad Yejjella
Department of Pharmaceutical Chemistry, University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530003, India
https://orcid.org/0000-0002-1449-6540
Kishore Bandarapalle
Department of Pharmaceutics, Sri Padmavathi School of Pharmacy, Tiruchanur, Tirupati-517503, India
https://orcid.org/0000-0003-0032-4331
Rajasekhar Komarla Kumarachari
Department of Pharmaceutical Chemistry, Sri Padmavathi School of Pharmacy, Tiruchanur, Tirupati-517503, India
https://orcid.org/0000-0001-5611-1410
Hari Veluru
MB School of Pharmaceutical Sciences (Erstwhile Sree Vidyanikethan Colege of Pharmacy), Mohan Babu University, Sree Sainath Nagar, A. Rangampeta, Tirupati-517102, India
https://orcid.org/0000-0003-0120-1923
Chilamakuru Naresh Babu
Raghavendra Institute of Pharmaceutical Education and Research, Ananthapuramu-515721, India
https://orcid.org/0000-0002-8496-053X

Corresponding Author(s) : Rajasekhar Komarla Kumarachari

komarla.research@gmail.com

Asian Journal of Chemistry, Vol. 36 No. 1 (2024): Vol 36 Issue 1, 2024

Abstract

In this study, five novel heterocyclic molecular hybrids (4a-e) were synthesized by combining benzofuran and isoxazole motifs. These
compounds were synthesized via a multistep process starting with 5-chlorosalicylaldehyde. The structures of the synthesized compounds were characterized by IR, 1H NMR and mass spectrometry. Computational tools were employed to predict properties, including antitubercular and antibacterial traits, drug-likeness, bioactivity scores, toxicity and potential molecular targets. In addition to these predictions, in vitro bioactivities were assessed and conducted Schrödinger docking simulations to determine binding affinities  to Mycobacterium tuberculosis enoyl-ACP reductase and Escherichia coli topoisomerase IV. Antitubercular efficacy was determined via the MABA method, while antibacterial effectiveness was tested against both Gram-positive and Gram-negative bacteria. The obtained  results highlighted the promise of these benzofuranyl-isoxazole hybrids, making them strong contenders for further lead optimization,  with the goal of developing more potent and safer pharmaceutical agents. 

Keywords

Benzofuran-isoxazole hybrids In vitro antitubercular activity Antibacterial activity Dual target docking
Posinasetty , B., Yejjella , R. P., Bandarapalle , K., Kumarachari, R. K., Veluru , H., & Babu , C. N. (2023). Benzofuran-Isoxazole Hybrids: Synthesis, Antimicrobial Activity and Dual Target Docking Studies. Asian Journal of Chemistry, 36(1), 125–134. https://doi.org/10.14233/ajchem.2024.30779
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. G. Bérubé, Expert Opin. Drug Discov., 11, 281 (2016); https://doi.org/10.1517/17460441.2016.1135125
  2. S. Maddela, G.E. Mathew, D.G.T. Parambi, F. Aljoufi and B. Mathew, Lett. Drug Des. Discov., 16, 220 (2019); https://doi.org/10.2174/1570180815666180516102100
  3. D.S. Reddy, M. Kongot and A. Kumar, Tuberculosis, 127, 102050 (2021); https://doi.org/10.1016/j.tube.2020.102050
  4. E. Kabir and M. Uzzaman, Results Chem., 4, 100606 (2022); https://doi.org/10.1016/j.rechem.2022.100606
  5. H. Khanam and Shamsuzzaman, Eur. J. Med. Chem., 97, 483 (2015); https://doi.org/10.1016/j.ejmech.2014.11.039
  6. B. Bhukya, A. Shukla, V. Chaturvedi, P. Trivedi, S. Kumar, F. Khan, A.S. Negi and S.K. Srivastava, Bioorg. Chem., 99, 103784 (2020); https://doi.org/10.1016/j.bioorg.2020.103784
  7. Z. Xu, S. Zhao, Z. Lv, L. Feng, Y. Wang, F. Zhang, L. Bai and J. Deng, Eur. J. Med. Chem., 162, 266 (2019); https://doi.org/10.1016/j.ejmech.2018.11.025
  8. A.A. Abbas and K.M. Dawood, Expert Opin. Drug Discov., 17, 1357 (2022); https://doi.org/10.1080/17460441.2023.2157400
  9. C. Mahecha-Mahecha, P. Borrego-Muñoz, L.M. Pombo and D. GambaSánchez, RSC Adv., 13, 25296 (2023); https://doi.org/10.1039/D3RA04737G
  10. Y. Chen, R. Chen, R. Yuan, L. Huo, H. Gao, Y. Zhuo, X. Chen, C. Zhang and S. Yang, Int. J. Mol. Sci., 24, 3575 (2023); https://doi.org/10.3390/ijms24043575
  11. A.A. Abbas and K.M. Dawood, RSC Adv., 13, 11096 (2023); https://doi.org/10.1039/D3RA01383A
  12. K.M. Dawood, Expert Opin. Ther. Pat., 29, 841 (2019); https://doi.org/10.1080/13543776.2019.1673727
  13. N.J. Siddiqui and M. Idrees, Der Pharma Chem., 6, 406 (2014).
  14. Y. Kanzouai, M. Laghmari, I. Yamari, R. Bouzammit, L. Bahsis, T. Benali, S. Chtita, M. Bakhouch, M. Akhazzane, M. El-Kouali, K. Hammani and G. Al Houari, J. Biomol. Struct. Dyn., 1 (2023); https://doi.org/10.1080/07391102.2023.2266022
  15. A. Nagaraju, S.K. Nukala, N.S. Thirukovela and R. Manchal, Chem. Biol. Lett., 10, 542 (2023).
  16. G.C. Arya, K. Kaur and V. Jaitak, Eur. J. Med. Chem., 221, 113511 (2021); https://doi.org/10.1016/j.ejmech.2021.113511
  17. F. Vafadarnejad, M. Saeedi, M. Mahdavi, A. Rafinejad, E. KarimpourRazkenari, B. Sameem, M. Khanavi and T. Akbarzadeh, Lett. Drug Des. Discov., 14, 712 (2017); https://doi.org/10.2174/1570180813666161018124726
  18. A. Saleem, U. Farooq, S.M. Bukhari, S. Khan, A. Zaidi, T.A. Wani, A.J. Shaikh, R. Sarwar, S. Mahmud, M. Israr, F.A. Khan and S.A. Shahzad, ACS Omega, 7, 30359 (2022); https://doi.org/10.1021/acsomega.2c03600
  19. K. Manna, Y.K. Agarwal and K.K. Srinivasan, Indian J. Heterocycl. Chem., 18, 87 (2008).
  20. N. Umapathi, B. Shankar, M. Raghavender, T. Vishnu and P. Jalapathi, Russ. J. Gen. Chem., 91, S112 (2021); https://doi.org/10.1134/S1070363222020256
  21. V.K. Kumar, V. Puli, K.R.S. Prasad and G. Sridhar, Chem. Data Coll., 36, 100787 (2021); https://doi.org/10.1016/j.cdc.2021.100787
  22. TB/COVID-19 Global Study Group, Eur. Respir. J., 59, 2102538 (2022); https://doi.org/10.1183/13993003.02538-2021
  23. T. Shah, Z. Shah, N. Yasmeen, Z. Baloch and X. Xia, Front. Immunol., 13, 909011 (2022); https://doi.org/10.3389/fimmu.2022.909011
  24. P. Daneshvar, B. Hajikhani, F. Sameni, N. Noorisepehr, N. Bostanshirin, F. Zare, S. Yazdani, M. Goudarzi, S. Sayyari and M. Dadashi, Heliyon, 9, e13637 (2023); https://doi.org/10.1016/j.heliyon.2023.e13637
  25. R.K. Kumarachari, M. Guruvareddy, M. Phebe, P.L. Reddy, M.S. Nithin, D. Lakshmipathi and M. Manasa, Asian J. Chem., 35, 617 (2023); https://doi.org/10.14233/ajchem.2023.27482
  26. A.V. Sadybekov and V. Katritch, Nature, 616, 673 (2023); https://doi.org/10.1038/s41586-023-05905-z
  27. D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, D.S. Druzhilovskii, A.V. Rudik, P.V. Pogodin and V.V. Poroikov, Chem. Heterocycl. Compd., 50, 444 (2014); https://doi.org/10.1007/s10593-014-1496-1
  28. A. Ayar, M. Aksahin, S. Mesci, B. Yazgan, M. Gül and T. Yýldýrým, Curr. Computeraided Drug Des., 18, 52 (2022); https://doi.org/10.2174/1573409917666210223105722
  29. T. Sander, Actelion’s Property Explorer, Allschwil, Switzerland: Actelion’s Pharmaceuticals Ltd. (2001).
  30. A. Daina, O. Michielin and V. Zoete, Sci. Rep., 7, 42717 (2017); https://doi.org/10.1038/srep42717
  31. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin and D.T. Mainz, J. Med. Chem., 49, 6177 (2006); https://doi.org/10.1021/jm051256o
  32. D. Eisenberg, R. Luthy and J.U. Bowie, Methods Enzymol., 277, 396 (1997); https://doi.org/10.1016/S0076-6879(97)77022-8
  33. C. Colovos and T.O. Yeates, Protein Sci., 2, 1511 (1993); https://doi.org/10.1002/pro.5560020916
  34. S. Analysis and V. Server (2011); Available from: http://nihserver.mbi.ucla.edu/SAVES/
  35. S.C. Lovell, I.W. Davis, W.B. Arendall 3rd, P.I. de Bakker, J.M. Word, M.G. Prisant, J.S. Richardson and D.C. Richardson, Proteins, 50, 437 (2003); https://doi.org/10.1002/prot.10286
  36. Cambridge Soft Corporation, a subsidiary of PerkinElmer, Inc. (2014). Chem DrawUltra version 8.0.3 for Windows. Available from: www. cambridgesoft.com.
  37. https://sourceforge.net/projects/openbabel/files/openbabel/2.4.0/; License: GNU GPL v2.
  38. N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch and G.R. Hutchison, J. Cheminform., 3, 33 (2011); https://doi.org/10.1186/1758-2946-3-33
  39. E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J.Y. Xiang, L. Wang, D. Lupyan, M.K. Dahlgren, J.L. Knight, J.W. Kaus, D.S. Cerutti, G. Krilov, W.L. Jorgensen, R. Abel and R.A. Friesner, J. Chem. Theory Comput., 12, 281 (2016); https://doi.org/10.1021/acs.jctc.5b00864
  40. S.G. Franzblau, R.S. Witzig, J.C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M.T. Degnan, M.B. Cook, V.K. Quenzer, R.M. Ferguson and R.H. Gilman, J. Clin. Microbiol., 36, 362 (1998); https://doi.org/10.1128/JCM.36.2.362-366.1998
  41. B. Aneja, M. Azam, A. Perwez, R. Maguire, U. Yadava, K. Kavanagh, S. Alam, C.G. Daniliuc, M.M.A. Rizvi, Q.M.R. Haq and M. Abid, ACS Omega, 3, 6912 (2018); https://doi.org/10.1021/acsomega.8b00582
  42. CLSI, M100 Performance Standards for Antimicrobial Susceptibility Testing, 29th ed. CLSI; Wayne, PA, USA (2019).
Read More
Author biographies is not available.
Download
AJC-36-1-17
Statistic
Read Counter : 0 Download : 0